Chairperson(s) : Sang-Hak Lee (Yonsei University, Republic of Korea)
Panel(s) : Nam Hoon Kim (Korea University, Republic of Korea), Jong-Chan Youn (The Catholic University of Korea, Republic of Korea), Dong-Hyuk Cho (Korea University, Republic of Korea)
-
Cutting-edge LP(a)-lowering therapies: how will they impact our practice?
Yu Mi Kang Harvard Medical School/TIMI Study Group, USA 08:30~08:50 -
Cutting-edge triglyceride-lowering therapies: can we close the gap in hypertriglyceridemia management?
Andre Zimerman Moinhos de Vento Hospital and College of Health Sciences, Brazil 08:50~09:10 -
Cutting-edge LDL-lowering therapies: where will the next-generation PCSK9 inhibitors stand?
Kyung Woo Park Seoul National University, Republic of Korea 09:10~09:30 - Panel Discussion 09:30~10:00
Chairperson(s) : YongSeek Park (Kyung Hee University, Republic of Korea), Chanbae Park (Ajou University, Republic of Korea)
Panel(s) : Jeonghan Kim (The Catholic University of Korea, Republic of Korea), Hyeongseok Kim (Chungnam National University, Republic of Korea), Chang-Myung Oh (GIST, Republic of Korea)
-
Cardiac-specific SERCA overexpression improves cardiac and systemic glucose metabolism during diabetes
Véronique Anne Lacombe Oklahoma State University, USA 13:00~13:20 -
ADAMTS4 elicits myeloid-derived immune cell recruitment and liver fibrogenesis in metabolic dysfunction-associated steatotic liver disease
Won Kim Seoul National University, Republic of Korea 13:20~13:40 -
Gene and cell therapies for metabolic disease
Il Minn University of Texas Southwestern Medical Center, USA 13:40~14:00 - Panel Discussion 14:00~14:30
